Mechanisms of reaction of L‐methionine with carboplatin and oxaliplatin in different media: a comparison with cisplatin
暂无分享,去创建一个
[1] A. Cailleux,et al. Kinetic studies of the reactivity between cisplatin and its monoaquo species with L-methionine , 1998 .
[2] S. Duffull,et al. Clinical Pharmacokinetics and Dose Optimisation of Carboplatin , 1997, Clinical pharmacokinetics.
[3] R. Carballar,et al. Stability study of carboplatin in aqueous solution and under illumination by high performance liquid chromatography. , 1997, Biomedical chromotography.
[4] S. Ghosh,et al. Kinetic analysis of the cis-diamminedichloroplatinum(II)--cysteine reaction: implications to the extent of platinum--DNA binding. , 1997, Journal of inorganic biochemistry.
[5] R. Rietbroek,et al. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. , 1996, Carcinogenesis.
[6] H. Ogata,et al. Decomposition Kinetics of Cisplatin in Human Biological Fluids , 1996, The Journal of pharmacy and pharmacology.
[7] Peter J. Sadler,et al. Ring-Opened Adducts of the Anticancer Drug Carboplatin with Sulfur Amino Acids. , 1996, Inorganic chemistry.
[8] B. Casetta,et al. Characterization of cisplatin-glutathione adducts by liquid chromatography-mass spectrometry. Evidence for their formation in vitro but not in vivo after concomitant administration of cisplatin and glutathione to rats anc cancer patients. , 1995, Journal of chromatography. B, Biomedical applications.
[9] P. Sadler,et al. [Pt(CBDCA-O)(NH3)2(L-Methionine-S)]: Ring-Opened Adduct of the Anticancer Drug Carboplatin ("Paraplatin"). Detection of a Similar Complex in Urine by NMR Spectroscopy , 1994 .
[10] L. Pendyala,et al. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. , 1993, Cancer research.
[11] P. Sadler,et al. Ring‐Opening Reactions of the Anticancer Drug Carboplatin: NMR Characterization of cis‐(Pt(NH3)2(CBDCA‐O)(5′‐GMP‐N7)) in Solution. , 1993 .
[12] J. Dorsey,et al. Determination of cisplatin and some possible metabolites by ion-pairing chromatography with inductively coupled plasma mass spectrometric detection. , 1993, Journal of chromatography.
[13] P. Sadler,et al. Cis-trans isomerization of [bis(L-methioninato)platinum]: metabolite of the anticancer drug cisplatin , 1993 .
[14] P. Sadler,et al. Studies of platinum(II) methionine complexes : metabolites of cisplatin , 1992 .
[15] M. Esposito,et al. Serial determination of platinum, protein content and free sulfhydryl levels in plasma of patients treated with cisplatin or carboplatin. , 1988, Anticancer Research.
[16] B. Corden. Reaction of platinum(II) antitumor agents with sulfhydral compounds and the implications for nephrotoxicity , 1987 .
[17] P. Dedon,et al. Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles. , 1987, Biochemical pharmacology.
[18] H. Pinedo,et al. Interaction of cisplatin and carboplatin with sodium thiosulfate: reaction rates and protein binding. , 1986, Clinical chemistry.
[19] D. Lydall,et al. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. , 1986, Cancer research.
[20] C. Riley,et al. Monitoring the reactions of cisplatin with nucleotides and methionine by reversed-phase high-performance liquid chromatography using cationic and anionic pairing ions. , 1983, Analytical biochemistry.
[21] F. Hochberg,et al. Trace analysis for cis-platinum anti-cancer drugs via LCEC. , 1983, Journal of chromatographic science.
[22] P. Daley-Yates,et al. The inhibition of renal ATPase by cisplatin and some biotransformation products. , 1982, Chemico-biological interactions.
[23] K. Kohn,et al. Mechanism of action of cis-dichlorodiammineplatinum(II). , 1979, Cancer treatment reports.
[24] B. Rosenberg. Anticancer activity of cis-dichlorodiammineplatinum(II) and some relevant chemistry. , 1979, Cancer treatment reports.
[25] BARNETT ROSENBERG,et al. Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode , 1965, Nature.
[26] T. Hambley,et al. Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin. , 1997, British Journal of Cancer.
[27] C. Louvet,et al. Place et intérêt de l'oxaliplatine dans les cancers colorectaux métastasés , 1997 .
[28] A. Cailleux,et al. Interactions between cisplatin derivatives and mobile phase during chromatographic separation , 1997 .
[29] J. Cradock,et al. Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions. , 1987, American journal of hospital pharmacy.
[30] A. Repta,et al. Exacerbation of cisplatin-induced nephrotoxicity by methionine. , 1984, Chemico-biological interactions.
[31] A. Balch,et al. 195Pt and 31P nuclear magnetic resonance studies of the binding of the cis-Pt(NH3)2+2 moiety to phosphate in aqueous solution , 1982 .
[32] A. Repta,et al. REACTIONS OF CISPLATIN WITH HUMAN PLASMA AND PLASMA FRACTIONS , 1980 .